Nature Outlook’s most recent issue is all on the opioid crisis. Here, Dr. Taylor discusses her work on opioids and the gut microbiome (article here).
Check out the full issue here.
The Taylor Lab is participating in a couple upcoming public lectures. These are great opportunities for the community to learn about our work in a fun, engaging environment.
First, the Neuroscience and Mental Health Institute at the University of Alberta is hosting a public lecture on the gut microbiome in health and disease. Lectures will cover what the gut microbiome is and its role in multiple sclerosis, spinal cord injury, and addiction. Dr. Taylor will be presenting her work on the gut microbiome and opioid use disorders. Lectures will be followed by an open question period.
This lecture is free and happens October 30th at 6pm in the Allard Lecture Hall in the Katz Building.
The Taylor lab will also be represented at the Telus World of Science Dark Matters Event. This is in adult-only event with a DJ, open bar, and local guest experts with interactive displays. This years theme is “Science of Drugs”, and the Taylor lab will be talking about how drugs interact with the brain and how we study them in the lab.
The event is October 3rd. Get your tickets here!
The Taylor lab was recently awarded a Canadian Foundation for Innovation JELF award that will help establish a cutting edge Pain and Addiction Laboratory at the University of Alberta.
This award will be used to purchase equipment for an advanced rodent behavioural testing facility, as well as imaging and molecular tools that will help us investigate underlying mechanisms contributing to chronic pain and opioid addiction.
Our lab was recently profiled in Folio. You can read it here.
We wrote a commentary on the recent paper looking at learned conditioned pain sensitivity in male and females (Martin et al). This study describes a novel paradigm to investigate the intersection between memory, pain, and stress, and demonstrates that placing mice or humans in an environment that was previously associated with pain can lead to heightened sensitivity in the absence of a painful stimulus. We comment on the implications of these results with regards to pain in men and women.
Well done, Zoe, a first-year Taylor lab Master’s student, for taking the lead on this effort. You can read the full commentary here.
Our new study is out now in the journal Neuropsychopharmacology. Here we examined the impact of opioids (morphine) on the community of symbiotic bacteria that reside in your gut (your gut microbiome). You can read more about this work in the recent news releases out in Nature Medicine and Pain Research Forum.
We found that morphine treatment significantly altered the abundance of certain bacteria in the gut. But, surprisingly, the effect on the gut microbiome was contingent on the regimen of morphine administration. Intermittent morphine (morphine injections spaced by repeated periods of withdrawal) had a completely different effect on the gut microbiome than sustained morphine (slow release morphine with no withdrawal periods). This suggests that opioid withdrawal – as well as opioids themselves – impact the gut microbiome, but do so in very distinct ways.
We went on to show that these changes in the gut microbiome are causally related to many of the symptoms of opioid dependence. We did this by treating control mice with a cocktail of oral antibiotics in order to deplete their own gut microbiome. We then recolonized their gut with fecal samples isolated from animals treated with intermittent
morphine. Recolonizing control mice with an “opioid” microbiome was sufficient to create cellular and behavioural changes that mimic an opioid dependent state. Control mice with an “opioid” gut microbiome exhibited inflammation in the brain and spinal cord, increased pain, and impairments in reward processing.
The results from this study are important because it suggests strategies that restore or manipulate the gut microbiome may be effective therapies for treating those suffering from opioid addiction. In particular, strategies to improve gut health during periods of opioid withdrawal may improve abstinence rates amongst those suffering from addiction.
Despite the lack of activity on this site, the Taylor lab is in full swing. We have an animal protocol, reagents, and fridges! We had two new graduate students join the lab in September (updates to come soon), along with several undergraduate researchers.
Last April, baby Willa made her appearance and took the honour as the the youngest Taylor lab member. While she’s a little young to pipette, she enjoys accompanying her mum (Anna) to the lab on occasion. Anna has been on maternity leave since April, and will be back in the lab full time in January.
If you are headed to SfN, come check out our newest data on Monday, November 5th in the session “Defining Dysbiosis in Disorders of Movement and Motivation” 8:30 am, where Anna will be presenting our project examining opioid-induced gut dysbiosis and the causal relationship with opioid dependent behaviours.
The walls have arrived, and we’re starting to look like a functional lab. Our first team of undergraduate students have been working hard at unpacking boxes and organizing chemicals.
Check out our brand new solution-making station. Next step – making some solutions!
I have officially started at the University of Alberta! While the lab space renovations have been delayed, I hope to have a working space by mid October. Stay tuned!
Well, I’m happy to say that I have a lab space. With windows to boot! Renovations are underway and we’re on track to be open for business as of September 2017. I’m looking forward to seeing those bench tops filled with equipment and students!